Subscription model for new antibiotics: fighting superbugs and drug resistance.
This Act establishes a novel subscription-based funding model to accelerate the development of new antimicrobial drugs targeting critical infections and drug resistance. The government will pay developers a fixed fee (between $750 million and $3 billion per contract) for access to these drugs, decoupling company revenue from sales volume. This aims to ensure a stable supply of life-saving treatments and enhance public health security against emerging superbugs.
Key points
Funding for Innovation: Allocates $6 billion to establish subscription contracts for companies developing critically needed antimicrobial drugs to combat resistance.
Guaranteed Supply: Companies receiving contracts must ensure continuous commercial availability and a reliable supply chain of the drug in the U.S.
Promoting Responsible Use: Creates grant programs for healthcare facilities to support judicious antimicrobial use, surveillance, and resistance monitoring.
Contract Value: Subscription contracts range from $750 million to $3 billion, adjusted based on the drug's favorable characteristics, such as treating multi-drug-resistant infections or having a novel mechanism.
Expired
Citizen Poll